| Budget Amount *help |
¥18,200,000 (Direct Cost: ¥14,000,000、Indirect Cost: ¥4,200,000)
Fiscal Year 2014: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2013: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2012: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2011: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000)
|
|---|
| Outline of Final Research Achievements |
Paying attention to the peptidic small molecule in which diverse pharmacological activity is expected, we performed a series of new integrated medicinal chemistry research to overcome intractable diseases such as cancer, genetic diseases and emerging infectious diseases.
Specific challenges are: (1) the design and synthesis of next-generation compounds of vascular disrupting agent (VDA) plinabulin which was developed by our group and is now in clinical trial, and the improvement of plinabulin as a prodrug that increases water-solubility and cancer tissue selectivity, (2) Development of a new chemotherapy for the treatment of nonsense-mediated genetic disease through the design and synthesis of new derivatives of natural product negamycin, which has a strong read-through activity, and (3) the design and synthesis of dipeptide type cysteine protease inhibitor for development of chemotherapy against severe acute respiratory syndrome (SARS).
|
